WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) has been named one of the Best Workplaces in Asia™ by Great Place to Work®, a global authority on high-trust, high-performance workplace cultures.
PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and laboratory services in greater China, such as a recently opened multi-functional lab in Suzhou. The best-workplaces honor recognizes PPD’s China-based business, known in the China drug development and contracting research marketplace by the Mandarin name Bai Shi Yi (百时益).
“We are honored to be recognized by Great Place to Work for the second time in less than a year,” said Ding Ming, Ph.D., vice president and general manager of PPD’s China operations. “This award further reinforces our strong reputation as a preferred employer in Greater China. We are committed to creating and maintaining a healthy and open environment for all employees, and we remain focused on recruiting highly qualified and engaging candidates and developing them continuously to serve our customers in China and around the world.”
Great Place to Work – which provides executive advisory and culture consulting services to businesses, nonprofits and government agencies – analyzes companies’ workplace programs and surveys over half a million employees across Asia and the Middle East about the key factors that create great workplaces. To be considered for the regional honor, companies must be identified as outstanding in their local country by appearing on one or more of the country-specific Best Workplaces lists. In 2020, Great Place to Work named PPD one of the Best Workplaces in Greater China™.
PPD continues to expand in the Asia-Pacific region to serve local and global customers, with operations located across 14 countries. In May, PPD held a grand opening ceremony for its new multipurpose laboratory in Suzhou, China, to support Western and China-based pharmaceutical and biotech companies managing China research studies. The 67,000-square-foot facility in the Suzhou New District, Jiangsu Province, offers bioanalytical, biomarker and vaccine laboratory services to support discovery research and clinical trials across all phases of pharmaceutical development. The new lab supplements the company’s Shanghai central lab, established in 2015.
In Japan, PPD-SNBL – the joint venture of PPD and Shin Nippon Biomedical Laboratories Ltd. (SNBL) – provides full-service capabilities for customers and is known as an industry leader in clinical trial delivery. PPD-SNBL has been recognized as a top-five growth business and desirable employer, and commended for its success with staff growth and retention, by Randstad Japan, a subsidiary of Randstad N.V., a global leader in the human resources services industry.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With more than 28,000 professionals worldwide, PPD has conducted clinical trials in more than 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; the risks related to the proposed merger of PPD by Thermo Fisher Scientific Inc.; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K and Quarterly Report on form 10-Q, which are available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.